BioPharmSignal logoBioPharmSignal

Biotech News

Biote Reports Fourth Quarter and Full Year 2025 Financial Results

biote Corp (BTMD)biote CorpEarnings

Executing efficiently on strategic priorities Continued salesforce expansion to capture large growth opportunity Anticipate a return to procedure revenue growth in the second half of 2026 Fourth Quarter 2025 Financial Highlights Revenue of $46.4 million Gross profit margin of 68.0% Net income of

Related news

BTMDbiote Corp2026-02-25 21:05 EST

Biote Schedules Fourth Quarter and Full Year 2025 Financial Results Release and Conference Call

BTMDbiote Corp2026-07-22 20:05 EST

Biote Schedules Second Quarter 2026 Financial Results Release and Conference Call

View all latest news

biote Corp

Hormone Optimization Biote operates a practitioner-led platform focused on hormone optimization and healthy aging. Its principal offering uses bioidentical hormone pellets implanted during office-based procedures. Practitioner Network The company trains and certifies medical practitioners, supplies procedure products and supports clinics...

Recent company news

BTMDbiote Corp2026-08-05 20:05 EST

Biote Reports Second Quarter 2026 Financial Results

BTMDbiote Corp2026-07-22 20:05 EST

Biote Schedules Second Quarter 2026 Financial Results Release and Conference Call

BTMDbiote Corp2026-06-01 12:00 EST

Biote Appoints Komal Bajaj, MD, MS as Chief Medical Officer

BTMDbiote Corp2026-05-28 13:00 EST

Biote Names Bob Peterson, Current Chief Financial and Chief Business Officer, as Interim CEO

BTMDbiote Corp2026-05-06 20:05 EST

Biote Reports First Quarter 2026 Financial Results

Stock data

Close
1.61 USD
Market cap
65.21M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States